

# **Use of mass spectrometry in the study of enzymes**

**Stephen Barnes, PhD**

**MCLM 452**

**sbarney@uab.edu**

**Sbarnes.uab@gmail.com**

Stephen Barnes BMG 744 02-21-06

## **Overview of class**

- Modification of the enzyme to regulate its activity
- Examining the chemistry of enzyme:substrate intermediates
  - Locating the site of inactivation of suicide inhibitors
- Reaction mechanism
  - Measuring all substrates and products
  - Enzyme kinetics
  - Stopped flow
- BAT, my kinda ‘zyme

Stephen Barnes BMG 744 02-21-06

## A good review of this topic

- Kelleher, NL and Hicks LM. Contemporary mass spectrometry for the direct detection of enzyme intermediates. *Current Opinion in Chemical Biology* 9: 424-430, 2005.

Stephen Barnes BMG 744 02-21-06

## Mass spectrometry and the study of enzymes

Enzymes often undergo posttranslational modifications in order to be active under the conditions in a cell

- for example, many enzymes in the signal transduction pathways are activated by phosphorylation on serine, threonine and tyrosine residues
- EGF receptor (tyrosine kinase), TGF beta type I receptor (serine kinase)
- sites of phosphorylation can be determined by mass spectrometry because of the increase in mass of  $m/z$  80 of peptides containing each phosphate group

Stephen Barnes BMG 744 02-21-06


## Enzymes and Mass Spec

Enzymes may undergo changes in structure once activated (see above) or during the reaction they catalyze

- this could be probed by H-D exchange experiments
- simulation of phosphorylation may be necessary by mutating serine and threonine groups to aspartate and glutamate, respectively

Stephen Barnes BMG 744 02-21-06


## MS of enzymes



Enzymes can be inactivated by suicide substrates - these come into the active site and undergo a covalent reaction, thereby blocking the approach of other substrate molecules

- to locate the region of the enzyme to which the suicide substrate is bound, carry out a trypsin digest and look for a peak that has undergone a molecular weight change (consistent with the structure of the suicide inhibitor)


Stephen Barnes BMG 744 02-21-06



### Reaction of chymotrypsin with tosyl phenylalanyl chloromethylketone (TPCK) in His57

CGVPA<sup>Q</sup>PVL SGLSRIVNGE EAVPGSWPWQ VSLQDKTGFH FCGGSLINEN 50  
 WVVTAAH<sup>C</sup>GV TTSDVVVAGE FDQGSSSEKI QKLKIAKVF<sup>K</sup> NSKYNSLTIN 100  
 NDITLLKLST AASFSQTVSA VCLPSASDDF AAGTTCVTTG WGLTRYTNAN 150  
 TPDRLLQQASL PLLSNTNCKK YWGTKIKDAM ICAGASGVSS CMGDSGGPLV 200  
 CKKNGAWTLV GIVSWGSSTC STSTPGVYAR VTALVNWVQQ TLAAN

Stephen Barnes BMG 744 02-21-06



**Chymotrypsin has a catalytic triad consisting of Asp102, His57 and Ser195**

**His57 is the site of reaction of chymotrypsin with TPCK to form a stable covalent bond, thereby acting as a suicide inhibitor**

Stephen Barnes BMG 744 02-21-06

## Possible proteases for locating TPCK-peptide

### Trypsin

CGVPAIQPVL SGLSRIVNGE EAVPGSWPWQ VSLQDK**TGFH FCGGSLINEN** 50  
**WVVTAAHCGV TTSDVVVAGE FDQGSSSEKI QKLKIAKVFK NSKYNSLTIN** 100  
NDITLLKLST AASFQTVSA VCLPSASDDF AAGTTCVTTG WGLTRYTNAN 150  
TPDRLQQASL PLLSNTNCKK YWGTKIKDAM ICAGASGVSS CMGDSGGPLV 200  
CKKNGAWTLV GIVSWGSSTC STSTPGVYAR VTALVNWVQQ TLAAN

### Glu-C


CGVPAIQPVL SGLSRIVNGE EAVPGSWPWQ VSLQDKTG**FCH** FCGGSLINEN 50  
**WVVTAAHCGV TTSDVVVAGE FDQGSSSEKI QKLKIAKVFK NSKYNSLTIN** 100  
NDITLLKLST AASFQTVSA VCLPSASDDF AAGTTCVTTG WGLTRYTNAN 150  
TPDRLQQASL PLLSNTNCKK YWGTKIKDAM ICAGASGVSS CMGDSGGPLV 200  
CKKNGAWTLV GIVSWGSSTC STSTPGVYAR VTALVNWVQQ TLAAN

### Chymotrypsin

CGVPAIQPVL SGLSRIVNGE EAVPGSWPWQ VSLQDKTG**FH** FCGGSLINEN 50  
**WVVTAAHCGV TTSDVVVAGE FDQGSSSEKI QKLKIAKVFK NSKYNSLTIN** 100  
NDITLLKLST AASFQTVSA VCLPSASDDF AAGTTCVTTG WGLTRYTNAN 150  
TPDRLQQASL PLLSNTNCKK YWGTKIKDAM ICAGASGVSS CMGDSGGPLV 200  
CKKNGAWTLV GIVSWGSSTC STSTPGVYAR VTALVNWVQQ TLAAN

Stephen Barnes BMG 744 02-21-06

## Advantage of growing recombinant bacteria on $^{12}\text{C}/^{14}\text{N}$ labeled substrates - protein is close to monoisotopic mass



Stephen Barnes BMG 744 02-21-06 Kelleher & Hicks, 2005

## Mass spectrometry and enzyme-catalyzed reactions


In the simplest case, an enzyme (E) reacts with a substrate (S) - an intermediate complex is formed (ES) and it is converted to an enzyme: product complex (E:P) before the product dissociates.



First order reaction - some second order reactions behave like a first order reaction when there is an excess of one substrate and the conversion of the other is <10%.

Stephen Barnes BMG 744 02-21-06

## Mass spectrometry and enzyme-catalyzed reactions




By measuring the molecular weights of the forms of the enzyme:substrate (product) complexes, mass spectrometry can throw enormous light on the mechanism

Stephen Barnes BMG 744 02-21-06

## Mass spectrometry and enzyme-catalyzed reactions

More typical reactions involve two substrates (S1 and S2) and two products (P1 and P2). The problem in this case is the order of addition

- is it a random mechanism? If so, both E.S1 and E.S2 exist
- is it an ordered mechanism? In this case, S1 has to bind first. So, there will be E.S1 and E.S1.S2, but no E.S2
- is it a Ping-Pong mechanism? In this case,  $E.S1 \rightarrow E.P1$  before S2 binds to form E.P1.S2



Stephen Barnes BMG 744 02-21-06


## Mass spectrometry and substrates and products of enzyme reactions

- Most enzyme reactions are studied by measuring the appearance of a product or (more rarely) the disappearance of a substrate
- If the substrate or product has a unique absorbance or fluorescence, the reaction can be followed in real time
- Some substrates have no usable absorbance or fluorescence - these can be measured using a radiolabeled substrate - the product is isolated by a solvent extraction procedure, or by HPLC or TLC. These reactions cannot be observed in real time
- Mass spectrometry has the advantage that it is capable of measuring all substrates and products, as well as the enzyme itself

Stephen Barnes BMG 744 02-21-06


## Sulfotransferase - a reaction with no absorbance or fluorescence to follow

Scheme 1: NodST Catalyzes the Sulfation of a Lipochitooligosaccharide (1)



Stephen Barnes BMG 744 02-21-06

## Sulfation of chitobiose



Stephen Barnes BMG 744 02-21-06

## Set up for the ST assay

Pi et al., Biochemistry 41:13283

- NodST purified by Ni-affinity chromatography
  - dialyzed against 100 mM Tris-HCl, pH 8.0 - 20 mM  $\beta$ -ME
  - Diluted into 10 mM NH<sub>4</sub>Ac buffer, pH 8.0
- Incubate (25  $\mu$ l) quenched with 100  $\mu$ l of MeOH containing internal standard
- Diluted incubate (40  $\mu$ l) introduced into ESI source at 20  $\mu$ l/min
- MS on a ThermoFinnigan LCQ monitoring *m/z* 503 and *m/z* 468 (internal standard)

Stephen Barnes BMG 744 02-21-06

## Kinetics of chitobiose ST by ESI-MS

Pi et al., Biochemistry 41:13283




FIGURE 3: Saturation plot of  $V_0$  vs [PAPS]. The inset is a double-reciprocal plot of  $1/V_0$  vs  $1/[PAPS]$  ([PAPS] = 1.25, 2.5, 3.5, 5, 12.5, 25, 40, and 50  $\mu\text{M}$ , [chitobiose] = 1 mM, [NodST] = 90 nM, and pH 8.0).

Stephen Barnes BMG 744 02-21-06

## Inhibition of ST by PAP using ESI-MS

Pi et al., Biochemistry 41:13283




FIGURE 5: Double-reciprocal plot of  $1/V_0$  vs  $1/[PAPS]$  at different PAP concentrations: 0  $\mu$ M PAP ( $\blacktriangle$ ), 0.75  $\mu$ M PAP ( $\blacksquare$ ), 1.5  $\mu$ M PAP ( $\bullet$ ), and 3.0  $\mu$ M PAP ( $\blacklozenge$ ) ([PAPS] = 1.25, 2.5, 5, 10, 25, and 50  $\mu$ M, [chitobiose] = 1 mM, [NodST] = 90 nM, and pH 8.0).


Stephen Barnes BMG 744 02-21-06

## Non-covalent enzyme:substrate complexes


- Shifting the enzyme from neutral pH conditions to the acidity of the spraying solution may break down the complex
- Spraying at neutral pH will increase the observed  $m/z$  values (the protein is less charged with protons)
- The larger  $m/z$  ions can be observed with an electrospray-TOF or a Qq TOF

Stephen Barnes BMG 744 02-21-06

## Schematic diagram of a stop-flow system




## Stopped flow set up




Stephen Barnes BMG 744 02-21-06

## Effect of the delay between V1 and V2 in a stopped flow experiment




In this reaction, hydrolysis of acetylcholine in an alkaline buffer is monitored by the ion at  $m/z$  146



Stephen Barnes BMG 744 02-21-06

Kolakowski and Konermann  
(Anal Biochem 292:107)

## Following a reaction using substrate and products ions in stopped flow ESI-MS




These data are from the conversion of chlorophyll A to pheophytin A (loss of Mg and gain of two protons).

The upper traces (A) are from the ESI-MS analysis. The lower traces (B) are from absorbance changes.

Stephen Barnes BMG 744 02-21-06

Kolakowski and Konermann  
(Anal Biochem 292:107)

## Unfolding kinetics of myoglobin by stopped-flow ESI-MS



The upper trace (A) is the 14th charge state of holo-myoglobin  $[M+14]^{14+}$  ( $m/z = 1255.9$ )

The reaction is created by a pH jump from 6.0 to 3.0. The lower trace (B) is the absorbance at 441 nm.

The estimated time constants for the bi-exponential process are 0.29/2.8 sec for A and 0.33/3.1 sec for B

Stephen Barnes BMG 744 02-21-06

Kolakowski and Konermann  
(Anal Biochem 292:107)

## Summary of the use of (real time) ESI-MS to follow enzyme reactions

- **The pros:**
  - All the substrates and products (as well as the enzyme itself) can be studied simultaneously
  - It's applicable to compounds with no absorbance or fluorescence
- **The cons:**
  - The buffer for the reaction has to be chosen very carefully
  - Ammonium salts are the best candidates, but they may have an effect on the reaction rates


Stephen Barnes BMG 744 02-21-06

## A practical example of use of MS in enzymology - the enzyme BAT



- Johnson et al., J Biol Chem, 266: 10227-10233, 1991 (human BAT enzyme - purification)
- Falany et al., J Biol Chem, 269: 19375-19379, 1994 (human cDNA cloning and expression)
- Falany et al., J Lip Res, 38: 86-95, 1997 (mouse - cDNA cloning and expression)
- He et al., J Lip Res, 44: 2242-2249, 2003 (rat - cDNA cloning, expression and localization)
- Sfakianos et al., J Biol Chem, 277: 47270-47275, 2002 (mechanism of human BAT)
- Shonsey et al., *Methods in Enzymology*, Vol. 400, Chapter 21, pp 360-373, 2005.
- Shonsey et al., *Methods in Enzymology*, Vol. 400, Chapter 22, pp 374-394, 2005.

Stephen Barnes BMG 744 02-21-06


## First let's remind ourselves of some basic biochemistry



Stephen Barnes BMG 744 02-21-06



## Bile acid N-acylamide formation (in hepatocytes)




Stephen Barnes BMG 744 02-21-06

## Characterization of BAT

- Purified from human liver cytosol 465-fold to a single protein band - retained the same ratio of glycine:taurine activity during purification
- Partial amino acid sequence and specific polyclonal antibody led to isolation of λgt11 clone from human liver cDNA library
- hBAT is a 418-aa protein; when expressed using a pKK233-2 vector in bacteria, it makes both glycine and taurine conjugates (and FBAL)

Stephen Barnes BMG 744 02-21-06




### Sequence comparisons of mouse, rat and human BATs

	*235
r 65%	SLLASHGFATLALAYWGYDDLPSRLEKVDLEYFEEGVFLLRHPKVLGPGVGILSV <b>CIGA</b> 238
m 63%	SLLASRGFATLALAYWNYDDLPSRLEKVDLEYFEEGVFLLRHPKVLGPGVGILSV <b>CIGA</b> 237
h 100%	<b>SLLASRGFASLALAYHNYEDLPRKPEVTDLEYFEEAAAN</b> FLLRHPKVF <small>GSGVGVVS</small> <b>CQGV</b> 238
r	EIGLSMAINLKQITATVTLINGPNFVSSNPHVYRGKVFQPTCSEEFVTTNALGLVEFYRT 298
m	EIGLSMAINLKQIRATVTLINGPNFVSSQSPHVYHGQVYPPVPSNEEFVVTNALGLVEFYRT 297
h	<b>QIGL</b> SMAIYLKQVTA <b>T</b> VTLINGTNFPFGIPQVYHGQIHQPLPHSAQ <b>L</b> I <b>S</b> TNALGL <b>L</b> E <b>L</b> YRT 288
*328	
r	FEETADKD <b>S</b> KYCFPIEKAHGHFLFVVGED <b>D</b> KNLN <b>S</b> KV <b>H</b> A <b>Q</b> A <b>I</b> A <b>Q</b> LM <b>K</b> SG <b>K</b> KNWTLLSYP 358
m	FQETADKD <b>S</b> KYCFPIEKAHGHFLFVVGED <b>D</b> KNLN <b>S</b> KV <b>H</b> AN <b>Q</b> A <b>I</b> A <b>Q</b> LM <b>K</b> NG <b>K</b> NNWTLLSYP 357
h	<b>FETT</b> QVGAS <b>Q</b> YL <b>F</b> PIEE <b>A</b> Q <b>Q</b> FL <b>F</b> IV <b>GEG</b> <b>D</b> KTINSKA <b>HAE</b> QA <b>I</b> G <b>Q</b> LRHG <b>K</b> NNWTLLSYP 358
*362                  *372	
r	GAG <b>G</b> LIEPPYSPL <b>C</b> SASRMPFVIP <b>S</b> INWGGEVIPH-AA 395
m	GAG <b>G</b> LIEPPYTPL <b>C</b> QASRMP <b>L</b> IPSLSWGGEVIPH <b>S</b> QA 395
h	GAG <b>G</b> LIEPPYSPL <b>C</b> ASTTHDLR--LHWGGEVIPH-AA 393

Stephen Barnes BMG 744 02-21-06

## Site-specific Cys mutations


- Mutations were prepared for the two conserved Cys residues (C235 and C372) in BATs
- C235Y hBAT had no enzyme activity
- C372A hBAT had low activity



Stephen Barnes BMG 744 02-21-06

Sfakianos et al.


## ESI-mass spectrum of hBAT products



Stephen Barnes BMG 744 02-21-06


Sfakianos et al.

## LC-MS of C372A hBAT product



Stephen Barnes BMG 744 02-21-06

## Metabolism in *E. coli* expression system



Stephen Barnes BMG 744 02-21-06


Sfakianos et al.

### hBAT Related Proteins from BLAST Search (Courtesy of Alexey Murzin, MRC lab)

kan-1	SLLASHGFATLALAYWGYDDLSRSLERKVDLEYFEEGVFLLRHPKVLGPGVGILSV <b>C</b> IGA	238
mBAT	SLLASRGFATLALAYWNYDDLPSRSLERKVDLEYFEEGVFLLRHPKVLGPGVGILSV <b>C</b> IGA	237
<b>hBAT</b>	SLLASRGFASLALAYHNYEDLPRKPEVTDLEYFEEAANFLLRHPKVFSGSGVGVSV <b>C</b> QGV	238
MTE-I	SLLAGKGFAVMALAYNNYDDLPKTMETMRIEYFEEAVNLYLRGHPEVKGP <i>G</i> IGLLGI <b>S</b> KGG	276
CTE-I	SLLAGKGFAVMALAYNNYDDLPKTMETMRIEYFEEAVNLYLRGHPEVKGP <i>G</i> IGLLGI <b>S</b> KGG	235
CLCTE	SLLAGKGFAVMALAYNNYDDLPKTMETMRIEYFEEAVNLYLRGHPEVKGP <i>G</i> IGLLGI <b>S</b> KGG	235
PLCTE	SLLAGKGFAVMALAYNNYEDLPKTMETLHLEYFEEAVNLYLSSHP <i>E</i> EVKGP <i>G</i> IGLLGI <b>S</b> KGG	235
PTE-Ia	SLLAGKGFAVMALAYNNYEDLPKDMDIIHLEYFEEAVTLYLSSHP <i>E</i> VTGSGVGVLG <b>I</b> <b>S</b> KGG	246
DLHp	KPFAEQGYAVALSYFAAPGLPATAEELPLEYFDRAVAWLAAQSPVDPKAIGVYGV <b>S</b> KGA	138
	<b>325</b>	
kan-1	ALGLVEFYR--TFEETAD-KDSKYCFPIEKAHGHFLFVGEDDKNLNSKVHAKQAIQLM	345
mBAT	ALGLVEFYR--TFQETAD-KDSKYCFPIEKAHGHFLFVGEDDKNLNSKVHANQAIQLM	344
<b>hBAT</b>	ALGLLELYR--TFETTQV-GASQYLFP <del>I</del> EEAQGQFLFIVGEGD <b>D</b> TKINSKAHA <b>E</b> QIQLK	345
MTE-I	KDGGLDVVE--ALQSPL--VDKKSFIPVERSDTTFLFLVGQDD <b>D</b> HNWKESEFYAREASKRLQ	382
CTE-I	KDGLKDVV--ALQSPL--VEQKSFIPVERSDTTFLFLVGQDD <b>D</b> HNWKESEFYANEISKRLQ	341
CLCTE	KDGLKDVV--ALQSPL--VEQKSFIPVERSDTTFLFLVGQDD <b>D</b> HNWKESEFYANEACKRLQ	343
PLCTE	KDGYADIVD--VLNSPLEGPDKS <b>F</b> IPVERAESTFLFLVGQDD <b>D</b> HNWKESEFYANEACKRLQ	354
PTE-Ia	KDGLKDIVD--LLNNP <del>L</del> LEGPDQKSLIPVERSDTAPFLFVGQDD <b>D</b> HNWKESEFYAREASKRLQ	354
DLHp	SNYMAFIYGLYDGTGLKAADAHQAAIPVEKIHGPVMLISGRADAMWSSSAMSDAVVRLK	258
	<b>362</b>	
kan-1	KSGKK-NWILLSYPGAG <b>H</b> LI <del>E</del> PPYSPLCSASRMPFVIPSIWGGEVIPH-AA	395
mBAT	KNGKK-NWILLSYPGAG <b>H</b> LI <del>E</del> PPYSPLCQASRMPILIPSLSGWGEVIPHQA	395
<b>hBAT</b>	RHGKN-NWILLSYPGAG <b>H</b> LI <del>E</del> PPYSPLCCASTTHDLR--LHWGGEVIPH-AA	393
MTE-I	AHGKE-KPQIICYPEAG <b>H</b> YI <del>E</del> PPYFPLCSAGMHLLVGANITFGGEPKPH-SV	432
CTE-I	AHGKE-KPQIICYPEAG <b>H</b> YI <del>E</del> PPYFPLCSAGMHLLVGANITFGGEPKPH-SV	391
CLCTE	AHGKE-KPQIICYPEAG <b>H</b> YI <del>E</del> PPYFPLCSAGMHLLVGANITFGGEPKPH-SV	391
PLCTE	AHGRR-KPQIICYPETG <b>H</b> YI <del>E</del> PPYFPLCRASLHALVGSP <i>E</i> IIWGGEPRAH-AM	393
PTE-Ia	AHGKE-KPQIICYPETG <b>H</b> YI <del>E</del> PPYFPLCKASLNSLVGGPVIWGGEPRAH-AM	404
DLHp	AKGFAHKVSHLAYPDAG <b>H</b> TAGMPALMGGSDK----GADEAVGGTVEGN-RF	304

Stephen Barnes BMG 744 02-21-06

### The Protein Structure Modeling of hBAT




Courtesy of Alexey Murzin, Center for Protein Engineering, MRC Cambridge, UK

Stephen Barnes BMG 744 02-21-06


## Cys235→Ser, what will C235S-BAT be, transferase or thioesterase?

235

kan-1	SILLASHGFATLALAYWGYDDLPSSRLEKVDLEYFEEGVFELLRHPKVLGPGVGILSV <b>C</b> IGA 238
mBAT	SLLASRGFATLALAYWNYDDLPSSRLEKVDLEYFEEGVFELLRHPKVLGPGVGILSV <b>C</b> IGA 237
hBAT	SLLASRGFASLALAYHNYEDLPSSRLEKVDLEYFEEGVFELLRHPKVFGSGVGVVSV <b>C</b> QGV 238
MTE-I	SLLAGKGFAMVALAYNYDDLPKTMETMR <sup>E</sup> IYFEEAVNYLRGHPEVKGP <sup>G</sup> IG <sup>L</sup> LG <b>I</b> S <b>K</b> GG 276
CTE-I	SLLAGKGFAMVALAYNYDDLPKTMETMR <sup>E</sup> IYFEEAVNYLRGHPEVKGP <sup>G</sup> IG <sup>L</sup> LG <b>I</b> S <b>K</b> GG 235
CLCTE	SLLAGKGFAMVALAYNYDDLPKTMETMR <sup>E</sup> IYFEEAVNYLRGHPEVKGP <sup>G</sup> IG <sup>L</sup> LG <b>I</b> S <b>K</b> GG 235
PLCTE	SLLAGKGFAMVALAYNYEDLPKTMETLHLEYFEEAMNYLLSHPEVKGP <sup>G</sup> VGLLG <b>I</b> S <b>K</b> GG 235
PTE-1a	SLLAGKGFAMVALAYNYEDLPKDMDIILHEYFEEAVTYLLSHPQVTGSGVGVLGI <b>S</b> <b>K</b> GG 246
DLhp	KPF <sup>A</sup> EQGYAVLALS <sup>F</sup> AA <sup>P</sup> GLPATAEELPLEYFDRAVANLAAQPSVDPKAIGVYGV <b>S</b> <b>K</b> GA 138







## Charge Relay Mechanism shared by hBAT, thioesterases, and a large group of hydrolases




Stephen Barnes BMG 744 02-21-06

Sfakianos, JBC 277:47270






## Kinetics of transferase and thioesterase activities of C235S hBAT variant with glycine



Stephen Barnes BMG 744 02-21-06

Sfakianos et al.

## LC-ESI-MS-MRM Analysis of Reaction Products



Stephen Barnes BMG 744 02-21-06

## Bile acid CoA:amino acid N-acyltransferase

- Has a ping-pong reaction mechanism
- Bile acid CoA undergoes a thioester interchange with Cys235-BAT
- Ser can replace Cys, but the complex is less stable
  - This can either lead to lowered activity, or increased turnover

Stephen Barnes BMG 744 02-21-06